Table 1.
Association between clinicopathologic characteristics and YWHAZ expression
| N | YWHAZ immunoreactivity | * P-value | |||
|---|---|---|---|---|---|
|
| |||||
| High expression | Low expression | ||||
| Total | 92 | 42 | 50 | ||
| Sex | Male | 71 | 31 (74%) | 40 (80%) | |
| Female | 21 | 11 (26%) | 10 (20%) | 0.4810 | |
| Age (y) | Mean | 67 (range:37-83) | |||
| <65 | 38 | 18 (43%) | 20 (40%) | ||
| >65 | 54 | 24 (57%) | 30 (60%) | 0.7816 | |
| Siewert type | Type II | 65 | 25 (60%) | 40 (80%) | |
| Type III | 27 | 17 (40%) | 10 (20%) | 0.0317 | |
| Histology | Differentiated | 50 | 23 (55%) | 27 (54%) | |
| Undifferentiated | 42 | 19 (45%) | 23 (46%) | 0.9417 | |
| Tumor size (mm) | <40 | 35 | 11 (26%) | 24 (48%) | |
| ≥40 | 57 | 31 (74%) | 26 (52%) | 0.0319 | |
| Venous invasion | v0 | 44 | 17 (40%) | 27 (54%) | |
| v1-3 | 48 | 25 (60%) | 23 (46%) | 0.1958 | |
| Lymphatic invasion | ly0 | 39 | 17 (40%) | 22 (44%) | |
| ly1-3 | 53 | 25 (60%) | 28 (56%) | 0.7333 | |
| TNM classification | |||||
| PT categories | pT1 | 28 | 8 (19%) | 20 (20%) | |
| pT2 | 11 | 4 (10%) | 7 (14%) | ||
| pT3 | 27 | 14 (33%) | 13 (26%) | ||
| pT4 | 26 | 16 (38%) | 10 (20%) | 0.0807 | |
| PN categories | pN0 | 51 | 18 (43%) | 33 (66%) | |
| pN1 | 9 | 4 (10%) | 5 (10%) | ||
| pN2 | 11 | 9 (21%) | 2 (4%) | ||
| pN3 | 21 | 11 (26%) | 10 (20%) | 0.0386 | |
| PStage | I | 34 | 10 (24%) | 24 (48%) | |
| II | 23 | 9 (21%) | 14 (28%) | ||
| III | 35 | 23 (55%) | 12 (24%) | 0.0079 | |
| Rucurrence | Absent | 62 | 22 (52%) | 40 (80%) | |
| Present | 30 | 20 (48%) | 10 (20%) | 0.0049 | |
Note: Statistically significant values are in boldface type.
*
P-values are from χ2 or Fisher’s exact test and were statistically significant at <0.05.